Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides.
Brett P. Monia(Ionis Pharmaceuticals (United States)), Susan M. Freier(Ionis Pharmaceuticals (United States)), Joseph F. Johnston(Ionis Pharmaceuticals (United States)), David J. Ecker(Harvard University), W.F. Lima(Ionis Pharmaceuticals (United States)), M.A. Zounes(Ionis Pharmaceuticals (United States))
Cited by 260
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
|Hepatology|2007|1k
Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression
|Journal of Biological Chemistry|1993|770